BTI BiOasis Technologies Inc

biOasis Technologies Inc. (TSX VENTURE:BTI) today is pleased to provide a 2012
year in review. biOasis has come a long way in 2012. The company has enjoyed a
steady, measured progression towards its goals in the execution of its science
and business objectives.


Through 2012 the company developed a powerful network of highly respected
contract research organizations that have helped conduct research, evaluate and
most importantly, validate biOasis' technology in pre-clinical studies. The
results of this work have positioned biOasis as an attractive partner for major
pharmaceutical companies working in the CNS sector. To this end, we have entered
into four collaborations with top tier pharmaceutical companies in England,
Belgium and the USA.


"I am very happy to give current investors and those who might consider biOasis
as part of their investment portfolio a brief, snap shot view of 2012 . . . its
not an easy assignment as the challenge is to provide this in a brief form,"
says CEO Rob Hutchison. "Our advancements over the past year have been so
important that it is difficult to condense them without leaving important points
out". "What the following reveals is a company that is moving forward with
resolve."


From its public inception in March 2008 to June of 2012, biOasis was very much
focused on validating its technology. Although our core technologies had been
vetted with solid research at The University of British Columbia amongst others,
it was important for biOasis to both affirm and advance our technology base with
additional scientific institutions and industrial partner organizations. This
was a critical step that was key to enable us to take the technology to
potential pharmaceutical partners - and attract the interest of those potential
partners to want to evaluate our technology for themselves.


Throughout 2012 we made some significant advances in understanding the potential
of our blood-brain barrier delivery technology. For example, we observed that
our Transcend vector can carry very large therapeutics, such as antibodies to
treat metastatic breast cancer, across the blood-brain barrier. World-renowned
experts at Texas Tech University, using specialized techniques, showed higher
transport rates than our initial findings. In addition, studies conducted by
third parties in 2012, showed that several other therapeutic compounds could be
transported across the blood-brain barrier.


With this knowledge and data in hand we created a non-confidential information
package that we began to circulate within the biopharmaceutical sector. The
interest thus generated has been remarkably strong. In the year 2012 alone we've
entered into collaboration agreements with four top tier pharmaceutical
companies. biOasis could not be happier with the companies so far on board and
with the continued industry interest leading into 2013. We've been asked by many
of you, "how long is the collaboration process?" Although varied and of
different time frames, the collaborative agreements are key to moving biOasis to
the next evolutionary phase of our business - seeing our technology migrate from
us to our pharmaceutical partners.


On a corporate note, the company is on a solid financial footing going into 2013
due in large part to prudent cash management, to funding of research by our
industry partners and to the raising of over $3.5 million through equity
financings. We also added a very seasoned financial and biotech business expert
to our Board of Directors and recently expanded our in-house science team to
position us to enter into additional industry collaborations in 2013.


In conclusion, although 2012 was a tough year in general in the world financial
markets and for many established and emerging companies, biOasis was recognized
as a TSX 2012 Venture 50(TM) company. The biOasis team had a plan entering into
2012: to affirm our technology and to engage industry - and to that end, we've
achieved the objectives that have resulted in a significant increase in
shareholder value.


On behalf of the biOasis board of directors and our team, we thank our investors
for their on-going support and we look forward to reporting on our
accomplishments in 2013.


ABOUT BIOASIS & TRANSCEND

biOasis Technologies Inc. is a biopharmaceutical company engaged in the
development and commercialization of products for the diagnosis and treatment of
neurological diseases and disorders. Its products and technologies are intended
for use within the healthcare and life science research markets. biOasis is
developing a proprietary carrier for the transport of therapeutic and imaging
agents across the blood-brain barrier - Transcend. Current initiatives within
the Transcend program include production of materials for preclinical studies
and conjugation to a range of small molecule and biologic therapeutics. To
address the unmet clinical need to transport drugs across the blood brain
barrier, biOasis intends to license Transcend to multiple corporate partners.


Forward Looking Statements

Certain statements in this press release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions. Such
forward-looking statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results, events or
developments, or industry results, to be materially different from any future
results, events or developments express or implied by such forward-looking
statements or information. Such factors include, among others, our stage of
development, lack of any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining regulatory
approval to market our products, the ability to protect our intellectual
property, dependence on collaborative partners and the prospects for negotiating
additional corporate collaborations or licensing arrangements and their timing.
Specifically, certain risks and uncertainties that could cause such actual
events or results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results expressed or
implied by such statements and information include, but are not limited to, the
risks and uncertainties that: we may not be able to successfully develop and
obtain regulatory approval for p97 as a Physician's Aid to Diagnose Alzheimer's,
or future products in our targeted corporate objectives; our future operating
results are uncertain and likely to fluctuate; we may not be able to raise
additional capital; we may not be successful in establishing additional
corporate collaborations or licensing arrangements; we may not be able to
establish marketing and the costs of launching our products may be greater than
anticipated; we have no experience in commercial manufacturing; we may face
unknown risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and other factors
as described in detail in our filings with the Canadian securities regulatory
authorities at www.sedar.com. Given these risks and uncertainties, you are
cautioned not to place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary statement.
All forward-looking statements and information made herein are based on our
current expectations and we undertake no obligation to revise or update such
forward- looking statements and information to reflect subsequent events or
circumstances, except as required by law.


On Behalf of the Board of Directors 

Rob Hutchison, Chairman & CEO

FOR FURTHER INFORMATION PLEASE CONTACT: 
biOasis Technologies Inc.
Rob Hutchison
Chairman & CEO
(778) 383-3280
rob@bioasis.ca
www.bioasis.ca

Grafico Azioni BiOasis Technologies (TSXV:BTI)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni BiOasis Technologies (TSXV:BTI)
Storico
Da Giu 2023 a Giu 2024